Cargando…
Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody
We investigated the efficacy of BNT162b2 mRNA COVID-19 vaccine in patients with B-cell malignancies treated with anti-CD20 antibody. Although T-cell-mediated immune responses were detected even in patients receiving R-CHOP treatment, the S1 antibody titer following BNT162b2 vaccination remained only...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Singapore
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8723797/ https://www.ncbi.nlm.nih.gov/pubmed/34981433 http://dx.doi.org/10.1007/s12185-021-03247-y |
| _version_ | 1784625796550230016 |
|---|---|
| author | Funakoshi, Yohei Yakushijin, Kimikazu Ohji, Goh Hojo, Wataru Sakai, Hironori Watanabe, Marika Saeki, Miki Hirakawa, Yuri Sakai, Rina Matsumoto, Sakuya Mizutani, Yu Kitao, Akihito Miyata, Yoshiharu Saito, Yasuyuki Kawamoto, Shinichiro Yamamoto, Katsuya Ito, Mitsuhiro Nishimura, Meiko Imamura, Yoshinori Kiyota, Naomi Matsuoka, Hiroshi Mori, Yasuko Minami, Hironobu |
| author_facet | Funakoshi, Yohei Yakushijin, Kimikazu Ohji, Goh Hojo, Wataru Sakai, Hironori Watanabe, Marika Saeki, Miki Hirakawa, Yuri Sakai, Rina Matsumoto, Sakuya Mizutani, Yu Kitao, Akihito Miyata, Yoshiharu Saito, Yasuyuki Kawamoto, Shinichiro Yamamoto, Katsuya Ito, Mitsuhiro Nishimura, Meiko Imamura, Yoshinori Kiyota, Naomi Matsuoka, Hiroshi Mori, Yasuko Minami, Hironobu |
| author_sort | Funakoshi, Yohei |
| collection | PubMed |
| description | We investigated the efficacy of BNT162b2 mRNA COVID-19 vaccine in patients with B-cell malignancies treated with anti-CD20 antibody. Although T-cell-mediated immune responses were detected even in patients receiving R-CHOP treatment, the S1 antibody titer following BNT162b2 vaccination remained only marginally increased for more than 3 years after the final dose of anti-CD20 antibody. We found no relationship between the percent of B-cells and S1 antibody titer. The duration of this suppression was much longer than we anticipated. Further protection and treatment strategies against COVID-19 for these patients are warranted. |
| format | Online Article Text |
| id | pubmed-8723797 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer Singapore |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87237972022-01-04 Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody Funakoshi, Yohei Yakushijin, Kimikazu Ohji, Goh Hojo, Wataru Sakai, Hironori Watanabe, Marika Saeki, Miki Hirakawa, Yuri Sakai, Rina Matsumoto, Sakuya Mizutani, Yu Kitao, Akihito Miyata, Yoshiharu Saito, Yasuyuki Kawamoto, Shinichiro Yamamoto, Katsuya Ito, Mitsuhiro Nishimura, Meiko Imamura, Yoshinori Kiyota, Naomi Matsuoka, Hiroshi Mori, Yasuko Minami, Hironobu Int J Hematol Rapid Communication We investigated the efficacy of BNT162b2 mRNA COVID-19 vaccine in patients with B-cell malignancies treated with anti-CD20 antibody. Although T-cell-mediated immune responses were detected even in patients receiving R-CHOP treatment, the S1 antibody titer following BNT162b2 vaccination remained only marginally increased for more than 3 years after the final dose of anti-CD20 antibody. We found no relationship between the percent of B-cells and S1 antibody titer. The duration of this suppression was much longer than we anticipated. Further protection and treatment strategies against COVID-19 for these patients are warranted. Springer Singapore 2022-01-04 2022 /pmc/articles/PMC8723797/ /pubmed/34981433 http://dx.doi.org/10.1007/s12185-021-03247-y Text en © Japanese Society of Hematology 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Rapid Communication Funakoshi, Yohei Yakushijin, Kimikazu Ohji, Goh Hojo, Wataru Sakai, Hironori Watanabe, Marika Saeki, Miki Hirakawa, Yuri Sakai, Rina Matsumoto, Sakuya Mizutani, Yu Kitao, Akihito Miyata, Yoshiharu Saito, Yasuyuki Kawamoto, Shinichiro Yamamoto, Katsuya Ito, Mitsuhiro Nishimura, Meiko Imamura, Yoshinori Kiyota, Naomi Matsuoka, Hiroshi Mori, Yasuko Minami, Hironobu Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody |
| title | Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody |
| title_full | Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody |
| title_fullStr | Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody |
| title_full_unstemmed | Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody |
| title_short | Limited increase in antibody titers following mRNA SARS-CoV-2 vaccination for more than 3 years after final dose of anti-CD20 antibody |
| title_sort | limited increase in antibody titers following mrna sars-cov-2 vaccination for more than 3 years after final dose of anti-cd20 antibody |
| topic | Rapid Communication |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8723797/ https://www.ncbi.nlm.nih.gov/pubmed/34981433 http://dx.doi.org/10.1007/s12185-021-03247-y |
| work_keys_str_mv | AT funakoshiyohei limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody AT yakushijinkimikazu limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody AT ohjigoh limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody AT hojowataru limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody AT sakaihironori limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody AT watanabemarika limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody AT saekimiki limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody AT hirakawayuri limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody AT sakairina limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody AT matsumotosakuya limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody AT mizutaniyu limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody AT kitaoakihito limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody AT miyatayoshiharu limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody AT saitoyasuyuki limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody AT kawamotoshinichiro limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody AT yamamotokatsuya limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody AT itomitsuhiro limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody AT nishimurameiko limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody AT imamurayoshinori limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody AT kiyotanaomi limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody AT matsuokahiroshi limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody AT moriyasuko limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody AT minamihironobu limitedincreaseinantibodytitersfollowingmrnasarscov2vaccinationformorethan3yearsafterfinaldoseofanticd20antibody |